DXNVX in Talks for Domestic Supply Agreement with Global Pharmaceutical Companies

DXVX is reportedly in discussions with a global pharmaceutical company regarding mutual cooperation plans for the domestic distribution of pharmaceuticals and the global export of DXVX healthcare products. Through this, they plan to further accelerate the growth of their domestic pharmaceutical distribution business, which has been operating since last year.

This year, DXVX has continuously expanded its pharmaceutical distribution business by selling its own brand antibiotics in the Chinese market, as well as supplying healthcare products and obesity specialty pharmaceuticals to over 1,000 hospitals, clinics, and pharmacies in Korea. Additionally, as a result of ongoing negotiations with leading overseas pharmaceutical companies regarding domestic supply rights, they recently announced that they are coordinating exclusive domestic sales rights with a top global pharmaceutical company and cooperation for the global expansion of DXVX healthcare products.

Currently, discussions are underway for the supply of more than 50 pharmaceutical products, including improved new drugs, generic drugs, non-reimbursed drugs, and over-the-counter drugs. For some pharmaceuticals that have not yet been introduced domestically, joint reviews are being conducted regarding domestic regulatory approval matters. Furthermore, through the global sales network of the global pharmaceutical company, they are simultaneously negotiating various global cooperation plans such as the distribution of 12 microbiome-based products and diagnostic kits developed by DXVX in Korea and Italy, open innovation related to new drug development, and joint investment in pipelines.

A company representative stated, “In the future, we plan to actively pursue the discovery of pharmaceuticals not yet introduced domestically by leveraging not only the exclusive domestic supply of global pharmaceutical products but also our company’s top-level capabilities related to pharmaceutical regulatory approval in Korea.” They added, “The pharmaceutical distribution business is expected to drive company growth alongside new drug development through the expansion and restructuring of the sales network and the development of additional pharmaceutical lineups.”

Meanwhile, DXVX aims to grow as a total healthcare solution provider encompassing diagnosis, treatment, prevention, and management through the growth of its microbiome-based biohealthcare, new drug development, and pharmaceutical distribution businesses.

This content was produced with the assistance of AI translation services.